Highlights
& Events
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Highlights
& Events
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Revenue trend 2018 - 2022 (million Euro)
No Data Found
Revenue by business unit 2018 - 2022 (million Euro)
No Data Found
Total Revenue split by Therapeutica area - FY 2022
(SPC 67.9%, Rare Disease 32.1%)
No Data Found
of € 237.2 million in FY 2022 and € 223.2 million in FY 2021
Pharmaceutical revenue (excluding Chemicals) split by Geographic - FY 2022
No Data Found
Key P&L Data
|
(million Euro)
|
FY 2022
|
|
FY 2021
|
|
FY 2020
|
|
FY 2019
|
|
FY 2018
|
|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
1,853.3
|
|
1,580.1
|
|
1,448.9
|
|
1,481.8
|
|
1,352.2
|
|
Gross Profit
as % of revenue |
1,286.6
69.4 |
|
1,152.3
72.9 |
|
1,042.0
71.9 |
|
1,044.9
70.5 |
|
956.7
70.7 |
|
Adjusted Gross Profit (1)
as % of revenue |
1,336.4
72.1 |
|
1,152.3
72.9 |
|
1,042.0
71.9 |
|
1,044.9
70.5 |
|
956.7
70.7 |
|
Operating Income (EBIT)
as % of revenue |
437.3
23.6 |
|
490.2
31.0 |
|
469.0
32.4 |
|
465.3
31.4 |
|
442.2
32.7 |
|
Adjusted Operating Income (Adj. EBIT) (2)
as % of revenue |
536.1
28.9 |
|
504.6
31.9 |
|
469.0
32.4 |
|
465.3
31.4 |
|
442.2
32.7 |
|
Net Income
as % of revenue |
312.3
16.9 |
|
386.0
24.4 |
|
355.0
24.5 |
|
368.9
24.9 |
|
312.4
23.1 |
|
Adjusted Net Income (3)
as % of revenue |
473.3
25.5 |
|
424.6
26.9 |
|
410.4
28.3 |
|
382.4
25.8 |
|
312.4
23.1 |
|
EBITDA (4)
as % of revenue |
672.8
36.3 |
|
602.3
38.1 |
|
569.3
39.3 |
|
544.0
36.7 |
|
499.1
36.9 |
2) Net income before income taxes, financial income and expenses, non-recurring items, and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3)
3) Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3) and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects
4) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3)
Balance Sheet at December 2022 (million Euro)
No Data Found
No Data Found
No Data Found
Net Debt - FY 2020 - 2022 (million Euro)
Net Debt / EBITDA1 - FY 2020 - 2022 (million Euro)
No Data Found
Free Cash Flow1 - FY 2020 - 2022 (million Euro)
No Data Found
Shareholders' Equity Per Share (Euro)
No Data Found
Adjusted Net Income Per Share (Euro)
No Data Found
Dividend per share (Euro)
No Data Found